InSilicoONCO Suite

InSilicoONCO Suite is a modeling and simulation platform designed to support and accelerate oncology drug development programs. By leveraging cutting-edge in silico technology, it enables pharmaceutical scientists and researchers to quantify efficacy-safety profiles, optimize dose regimens, and conduct virtual clinical trials — all in a cost-effective, pay-per-use environment that requires no prior computational expertise.

The platform bridges the gap between academic science and the pharmaceutical industry by integrating validated, regulatory-approved models into streamlined workflows. It is built to be scalable and accessible, making advanced modeling and simulation capabilities available to a broad range of life sciences professionals working in oncology drug development.

Core Platform Capabilities

• Quantify the efficacy and safety profile of new drug candidates and compare them against existing therapies
• Optimize dose regimens through in silico clinical trials conducted in virtual patient populations
• Explore novel clinical scenarios not previously considered in real-world trials
• Assess the efficacy and safety of anti-cancer treatments and optimize treatment scheduling
• Characterize dose-exposure-response relationships to inform clinical decision-making
• Guide the design of clinical studies, including optimization of scheduling, study duration, and the number of subjects and cohorts

Platform Features

• Crowdscience approach: Integrates validated and regulatory-approved models, connecting scientific innovation with industry application
• Scalable infrastructure: Flexible computational power with no fixed software costs; models are available on a pay-per-use basis
• User-friendly interface: Streamlined workflows and an intuitive user interface allow scientists without computational backgrounds to run complex models independently

Products Within the InSilicoONCO Suite

• PCa GnRH Agonists Simulator: Simulates the effect of GnRH agonists on testosterone levels and enables in silico clinical trials within a virtual population of prostate cancer patients
• CTX NeutroSim: Performs in silico clinical trials to assess the neutropenic effects of chemotherapeutic agents in a virtual population of cancer patients

The InSilicoONCO Suite is delivered as an online platform, removing the need for local software installation and enabling flexible access for research and development teams. Its regulatory-aligned modeling framework makes it suitable for use in formal drug development programs where simulation data may support clinical and regulatory submissions.